COVID-19 News: Corona makes a comeback; new PJ.2.1 variant detected in 18 countries..

Between 2020 and 2023, the world faced the perilous phase of the COVID-19 pandemic. While the virus responsible for COVID-19 is no longer as potent as it once was, the emergence of new variants—resulting from periodic mutations—continues to be a cause for concern. After remaining relatively dormant for about a year, the virus is once again making headlines due to the appearance of new, mutated variants.

A new COVID-19 variant, designated PJ.2.1, has recently gained attention. Reports indicate that approximately 24 mutations have been identified in its spike protein. Furthermore, it has already been detected in 18 countries. The rising number of cases in Canada and the United States has recently drawn the attention of scientists.

Given the potential risks associated with this new strain, the World Health Organization (WHO) has classified it as a "variant under monitoring." Although experts suggest that there is no immediate, major global threat, the emergence of this new variant has reignited questions and concerns regarding COVID-19.

Can this new variant evade existing immunity? Are current vaccines effective against it, and could it lead to more severe infections? Let us examine the key details surrounding PJ.2.1.

The New Coronavirus Variant: PJ.2.1

The WHO has categorized the new coronavirus variant, PJ.2.1, as a "variant under monitoring." According to reports, it is a derivative of the JN.1 variant, with 24 mutations identified in its spike protein—the component the virus uses to enter human cells.

As of November 8, this variant had been detected in 18 countries. Discussions surrounding this strain of the virus have intensified following a rise in cases in Canada and the United States.

The WHO’s Technical Advisory Group on Virus Evolution (TAG-VE) stated in its preliminary report that the global health risk posed by this new variant is currently considered low. However, further assessment is required, as sufficient data is not yet available.

Laboratory studies suggest that PJ.2.1 may be similar to other existing variants; it does not show any significant change in its ability to evade antibodies.
Furthermore, blood samples from individuals who received COVID-19 vaccines—updated in recent years to target variants like LP.8.1 and XFG—have shown the capacity to neutralize this strain.
This indicates that existing vaccines may be effective in mitigating the risks associated with this virus.

What does the WHO say?

According to the WHO report, this variant was first identified in Canada. Laboratory studies indicate that it may bind more strongly to the ACE2 receptor in the human body compared to previous strains. It is important to note that the ACE2 receptor acts as a gateway on the surface of human cells, which the coronavirus uses to gain entry.

While the virus’s stronger binding to the receptor could be one reason for the increase in cases, it does not definitively prove that it spreads more rapidly among humans.
As of November 8, 722 samples of this variant from 18 countries had been recorded in scientific databases.

Could PJ.2.1 pose a risk of severe illness?

According to the WHO, there is currently no evidence to suggest that PJ.2.1 causes more severe illness than previous variants. However, data from patients remains limited at this stage. Further studies are being conducted to understand this variant.

Medical reports indicate that a study was carried out on blood samples from 36 individuals who had received vaccines developed for previous variants. It was found that the antibodies in their blood showed a decent capacity against the PJ.2.1 variant.

PC Social Media